How many decades is this going to take to get it proven in humans? I'm betting 100 years because we have shit for brains in our stroke associations with NO strategy and no way to solve any of the problems in stroke.
http://www.news-medical.net/news/20150319/MTfp-c2adsiRNA-reduces-blood-vessel-infarct-improves-overall-brain-activity-in-ischemic-stroke-model.aspx
BIOASIS TECHNOLOGIES INC. (OTCQX:BIOAF; TSX.V:BTI), a
pioneering biopharmaceutical company focused on overcoming the
limitations of therapeutic drug delivery across the blood-‐brain
barrier (BBB), announces the results from an animal ischemic stroke
model performed at the National Research Council Canada with the biOasis
Transcend carrier peptide, MTfp and siRNA (MTfp-‐siRNA). Two key
therapeutic effects were shown with MTfp-‐siRNA; A high degree of
reduction of the area of blood vessel infarct and improvement of overall
brain activity as determined by neurological scoring.
On July 25th, 2014, biOasis announced that its newly discovered
carrier peptide (MTfp), part of the biOasis Transcend family of carrier
technologies, effectively delivered siRNA across the BBB and into brain
cells. The company also announced that it achieved the goal of silencing
the expression of a selected target gene in the brain by approximately
50%. This study prompted the company to move to a model of disease where
therapeutic effects could be measured.
Ischemic stroke is the most common type of stroke in humans and an
animal model that mimics stroke was chosen to establish the
effectiveness of MTfp-‐siRNA treatment administered immediately prior
to induction of ischemic stroke.
Key Findings of Ischemic Stroke Model Treated with MTfp-‐siRNA:
(1) The area of infarct (damage) was highly reduced in the animals
treated with MTfp-‐siRNA. Brain images revealed significantly less
stroke damage in brain sections from animals treated with the
MTfp-‐siRNA when compared to the same brain regions in the control
animals. The brain section images may be viewed below. The images show
that there is more stroke damage (white areas) in the five sections from
control animals (Left Panel) when compared to the same brain regions in
the animals with stroke treated with the MTfp-‐siRNA (Right Panel).
(2)
Thirty-‐minutes after induction of stroke, the neurological scores of
the animals treated with the MTfp-‐siRNA were significantly better than
those of control animals. At 24 hours, controls animals demonstrated a
slight improvement in neurological scores while MTfp-‐siRNA treated
animals showed a vast improvement and exhibited nearly normal
neurological scores.
“The results clearly demonstrate that in an established animal model
of stroke, therapeutic levels of siRNA that down-‐regulate the
expression of a key pathogenic gene were successfully delivered by MTfp
to the brain, resulting in a significant reduction of infarct damage and
improvement of neurological scores associated with healthy brain
function,” said Dr. Wilfred Jefferies, biOasis Founding Scientist.
No comments:
Post a Comment